Skip to main content
. 2019 Dec 2;9:18126. doi: 10.1038/s41598-019-54402-9

Figure 3.

Figure 3

Overall survival among HR+/HER2+ metastatic breast cancer patients treated with chemotherapy + anti-HER2 therapy or hormonal therapy + anit-HER2 therapy. Chemo, chemotherapy; HR, hormone receptor; HER, human epidermal growth factor.